<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04493762</url>
  </required_header>
  <id_info>
    <org_study_id>UW19-839</org_study_id>
    <nct_id>NCT04493762</nct_id>
  </id_info>
  <brief_title>Liver Fibrosis and Gut Microbiota in Patients With Psoriasis Vulgaris and Rheumatoid Arthritis on Methotrexate</brief_title>
  <official_title>A Comparison Study of Liver Fibrosis and Its Association With Gut Microbiota in Patients With Psoriasis Vulgaris and Rheumatoid Arthritis on Methotrexate</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>The University of Hong Kong</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>The University of Hong Kong</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      While methotrexate (MTX) remains a treatment of choice for patients with rheumatoid arthritis&#xD;
      (RA), psoriasis (PsO) and psoriatic arthritis (PsA), long-term MTX use has been shown to be&#xD;
      associated with liver fibrosis and cirrhosis in these patients. In addition, gut dysbiosis&#xD;
      has been found to be associated with liver fibrosis and cirrhosis via the gut-liver axis,&#xD;
      underscoring the potential role of gut microbiota and bacterial translocation in the&#xD;
      pathogenesis of chronic liver diseases in these patients.&#xD;
&#xD;
      In this study, we aim to assess the prevalence of advanced liver fibrosis or cirrhosis among&#xD;
      these patients on MTX treatment compared to those without, using transient elastography. We&#xD;
      also aim to identify the possible risk factor(s) for advanced liver fibrosis or cirrhosis&#xD;
      among them. Further, we aim to characterize the difference in fecal microbiota patterns among&#xD;
      these three groups of patients.&#xD;
&#xD;
      Using a cross-sectional, prospective cohort design, this study will enroll approximately 600&#xD;
      eligible patients, including 300 patients with PsO/PsA and 300 patients with RA, to examine&#xD;
      the following hypotheses:&#xD;
&#xD;
        1. Patients on higher cumulative dose of MTX will have higher prevalence of advanced liver&#xD;
           fibrosis or cirrhosis compared to those on lower cumulative dose of MTX;&#xD;
&#xD;
        2. Patients with MTX use will have higher prevalence of advanced liver fibrosis or&#xD;
           cirrhosis compared to those without MTX use;&#xD;
&#xD;
        3. The fecal microbiota composition will be different between patients with and without MTX&#xD;
           treatment; and&#xD;
&#xD;
        4. The fecal microbiota composition will be different between patients with and without&#xD;
           advanced fibrosis/cirrhosis while on MTX treatment.&#xD;
    </textblock>
  </brief_summary>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">August 13, 2020</start_date>
  <completion_date type="Anticipated">December 11, 2022</completion_date>
  <primary_completion_date type="Anticipated">December 12, 2021</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Cross-Sectional</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>The number of patients with advanced liver fibrosis or cirrhosis</measure>
    <time_frame>At the time of the assessment procedure</time_frame>
    <description>We will measure the number of patients with significant fibrosis (defined as having liver stiffness â‰¥ 7.5 kPa in transient elastography), and among those who undergo biopsy, the number of patients whose biopsy specimen is of Roenigk grades 3b or 4</description>
  </primary_outcome>
  <primary_outcome>
    <measure>The type and abundance of fecal microbiota patterns</measure>
    <time_frame>At the time of the assessment procedure</time_frame>
    <description>We will measure the type and abundance of various bacteria/viruses in specimens; alpha diversity within a specimen and beta diversity between groups of specimen; specific taxa that differ significantly between groups; and metabolic profiles and functional pathways associated with change in gut microbiota</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>The risk factors of liver fibrosis</measure>
    <time_frame>At the time of the assessment procedure</time_frame>
    <description>Risk factors to be examined will include demographic variables such as age and gender, cumulative dose of MTX, gut dysbiosis, duration of disease, co-morbidities, hepatic steatosis, liver stiffness, and other potential factors</description>
  </secondary_outcome>
  <number_of_groups>2</number_of_groups>
  <enrollment type="Anticipated">600</enrollment>
  <condition>Psoriasis Vulgaris</condition>
  <condition>Rheumatoid Arthritis</condition>
  <condition>Fibrosis, Liver</condition>
  <arm_group>
    <arm_group_label>PSO/PSA</arm_group_label>
    <description>Patients diagnosed with psoriasis or psoriatic arthritis</description>
  </arm_group>
  <arm_group>
    <arm_group_label>RA</arm_group_label>
    <description>Patients diagnosed with rheumatoid arthritis</description>
  </arm_group>
  <biospec_retention>Samples With DNA</biospec_retention>
  <biospec_descr>
    <textblock>
      Blood (serum and plasma) and stool samples collected for this study will be saved for 3 years&#xD;
      and stored at - 80 degree Celsius in the laboratory in Hong Kong for biomarker analyses.&#xD;
    </textblock>
  </biospec_descr>
  <eligibility>
    <study_pop>
      <textblock>
        All patients who have regular follow up in Dermatology/ Rheumatology clinics of Queen Mary&#xD;
        Hospital, with a diagnosis of PsO/PsA and/or RA will be identified and screened for&#xD;
        eligibility.&#xD;
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Age between 18 to 85 years&#xD;
&#xD;
          -  Have regular follow up in Dermatology/ Rheumatology clinics of Queen Mary Hospital&#xD;
&#xD;
          -  Diagnosed with PsO/PsA or RA&#xD;
&#xD;
          -  Chinese ethnicity&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Age below 18 years or above 85 years&#xD;
&#xD;
          -  Known decompensated cirrhosis&#xD;
&#xD;
          -  Pregnancy or breastfeeding&#xD;
&#xD;
          -  Unstable medical illness or active infection&#xD;
&#xD;
          -  Unable to provide written consent&#xD;
&#xD;
          -  Unable to adhere to the protocol&#xD;
&#xD;
          -  Unable to read and/or write Chinese language&#xD;
&#xD;
          -  On anticoagulant/ antiplatelet treatment&#xD;
&#xD;
          -  Abnormal platelet count &lt;150&#xD;
&#xD;
          -  Known disease/condition with prolonged INR/bleeding tendency&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>85 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Sze-Man Wong, MSc, MRCP</last_name>
    <role>Principal Investigator</role>
    <affiliation>Queen Mary Hospital, Hong Kong</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Sze-Man Wong, MSc, MRCP</last_name>
    <phone>+852 22555154</phone>
    <email>wongsm11@ha.org.hk</email>
  </overall_contact>
  <verification_date>July 2020</verification_date>
  <study_first_submitted>July 15, 2020</study_first_submitted>
  <study_first_submitted_qc>July 27, 2020</study_first_submitted_qc>
  <study_first_posted type="Actual">July 30, 2020</study_first_posted>
  <last_update_submitted>July 27, 2020</last_update_submitted>
  <last_update_submitted_qc>July 27, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">July 30, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Queen Mary Hospital, Hong Kong</investigator_affiliation>
    <investigator_full_name>Dr. Sze-Man Wong</investigator_full_name>
    <investigator_title>Associate Consultant</investigator_title>
  </responsible_party>
  <keyword>Methotrexate</keyword>
  <keyword>Microbiota</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Arthritis</mesh_term>
    <mesh_term>Arthritis, Rheumatoid</mesh_term>
    <mesh_term>Liver Cirrhosis</mesh_term>
    <mesh_term>Psoriasis</mesh_term>
    <mesh_term>Fibrosis</mesh_term>
  </condition_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

